Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry

FOSTER CITY, CA / ACCESSWIRE / February 20, 2024 / Gilead Sciences, Inc. (Nasdaq:GILD) announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.

“We have set ambitious goals that are helping to further embed corporate responsibility into our business and honor our commitment to create a better world for future generations,” said Carmen Villar, Vice President, Public Affairs, Gilead Sciences. “We are proud to cultivate sustainable practices and an inclusive culture, while providing equitable opportunities for the communities we serve.”

Gilead’s Environmental, Social and Governance (ESG) strategy aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner. Examples of Gilead’s commitment to ESG include:

  • Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial support
  • Increasing access to medicines in low- and lower-middle income countries, including voluntary licensing for Gilead’s HIV, hepatitis C and COVID-19 treatments
  • Creating an inclusive workplace that is representative of the diverse communities the company serves
  • Continuing to evolve the company’s environmental sustainability program while progressing against ambitious goals focused on carbon, water, waste and packaging

Each year, JUST Capital collects and analyzes corporate data to evaluate the 1,000 largest public U.S. companies across 20 issues identified through comprehensive, ongoing public opinion research on Americans’ attitudes toward responsible corporate behavior. For more about the JUST Capital rankings, visit: https://justcapital.com/reports/just-capital-and-cnbc-release-the-2024-rankings-of-americas-most-just-companies/

This recognition follows Gilead’s recent announcement it was named to the Dow Jones Sustainability World Index for the third consecutive year, as well as the Dow Jones Sustainability North America Index, which highlight the most sustainable companies around the world based on a corporate sustainability assessment.

Details on Gilead’s ESG commitments, goals and progress can be found in the company’s Environmental Social Governance Impact Report, which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead’s commitment to ESG at https://www.gilead.com/purpose/esg.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Jacquie Ross, Investors
investor_relations@gilead.com

Meaghan Smith, Media
public_affairs@gilead.com

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:

Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Staff

Recent Posts

Therma Bright Q2, 2024 Market Update On Business

Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by…

44 mins ago

Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences

The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…

2 hours ago

High-Growth Industries with 25%-30% CAGR Growth Over the Next Five Years

BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…

2 hours ago

Bioz Brings Cutting-Edge AI Citation Widgets to Precision X-Ray, Inc.’s Product Pages

PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…

2 hours ago

iZafe Group Receives Confirmed Order of 500 Dosell Units from Ti Medi

STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…

2 hours ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…

5 hours ago